VIYASH Viyash Scientific Q1 FY26 results (Apr–Jun 2025) and concall
Viyash reported a strong Q1 FY26 with revenue growing 4% year-on-year to INR353 crores and adjusted EBITDA increasing 19% to INR68 crores, driven by margin expansion to 19.5%. The combined entity with Sequent Scientific also demonstrated robust performance, with revenue up 8.7% and EBITDA up 21% year-on-year, and a significant improvement in net debt to EBITDA to 0.6x. The merger process is progressing as planned, and the company successfully navigated multiple regulatory audits, highlighting its strong quality culture.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 42 | 338 | 42 | 328 |
| EBITDA | -2 | 58 | -3 | 49 |
| Net profit | 4 | 51 | 4 | 17 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
